delivery within 72 Hours
BISLERI CHEWBAL TABLET
₨ 489
Generic: Iron hydroxide polymaltose complex & folic acid
Pack Size: 30
Product Form: Tablet
Delivery within: 2 to 3 working days across Pakistan
Shipping & Delivery
-
Courier delivery
Our courier will deliver to the specified address
2-3 Days
From Rs 250
-
Free 15-Day returns
Black Friday Blowout!
Description
Bisleri Chewbal Tablet is a dietary supplement that contains Iron hydroxide polymaltose complex & folic acid. It is a chewable tablet that is designed to provide essential nutrients to the body. It is a great way to supplement your daily diet with essential vitamins and minerals.
Uses:
Bisleri Chewbal Tablet is used to treat iron deficiency anemia. It helps to replenish the body’s iron stores and helps to prevent further iron deficiency. It is also used to treat folic acid deficiency, which can lead to anemia. It helps to prevent neural tube defects in pregnant women.
Side Effects:
Bisleri Chewbal Tablet is generally well tolerated. However, some people may experience side effects such as nausea, vomiting, constipation, diarrhea, stomach pain, and dark stools. If you experience any of these side effects, contact your doctor immediately.
When Not to Use:
Bisleri Chewbal Tablet should not be used if you are allergic to any of the ingredients in the tablet. It should also not be used if you have any pre-existing medical conditions such as kidney disease, liver disease, or heart disease. It should also not be used if you are pregnant or breastfeeding.
Conclusion:
Bisleri Chewbal Tablet is a dietary supplement that contains Iron Hydroxide Polymaltose Complex and Folic Acid. It is used to treat iron deficiency anemia and folic acid deficiency. It is generally well tolerated, but some people may experience side effects. It should not be used if you are allergic to any of the ingredients, have any pre-existing medical conditions, or are pregnant or breastfeeding.
Customer Reviews
You must be logged in to post a review.


Reviews
Clear filtersThere are no reviews yet.